(FM) Oncología
Departamento académico
Josep
Tabernero Caturla
Publicacions en què col·labora amb Josep Tabernero Caturla (19)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
2023
-
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors
Science translational medicine, Vol. 15, Núm. 695, pp. eabp9229
2021
-
A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors
Radiology, Vol. 299, Núm. 1, pp. 109-119
-
Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology
ESMO Open
-
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
European Journal of Cancer, Vol. 155, pp. 168-178
2020
-
Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria
Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909
-
Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial
Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317
2019
-
Early evolutionary divergence between papillary and anaplastic thyroid cancers
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 11, pp. 1843
-
Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials
Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471
2018
-
Early evolutionary divergence between papillary and anaplastic thyroid cancers
Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460
-
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer
Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629
-
The safety of ramucirumab for the treatment of colorectal cancer
Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951
2017
-
Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights
Molecular Oncology, Vol. 11, Núm. 9, pp. 1263-1272
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97
2016
-
Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer
Expert Opinion on Emerging Drugs, Vol. 21, Núm. 3, pp. 267-282